Holen Sie sich die Stockscreener-App
1.68
2.44%
0.04
Vorhandelsmarkt:
1.82
0.14
+8.33%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.69
24-Stunden-Volumen:
251.32K
Relative Volume:
1.19
Marktkapitalisierung:
$27.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-2.40
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
+20.43%
1M Leistung:
+25.37%
6M Leistung:
+41.18%
1J Leistung:
-14.29%
1-Tages-Spanne:
$1.6407
$1.70
1-Wochen-Bereich:
$1.41
$1.70
52-Wochen-Spanne:
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.68 | 22.42M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
NanoViricides Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
What analysts say about NanoViricides Inc. stockExceptional stock performance - jammulinksnews.com
What drives NanoViricides Inc. stock priceBreakneck growth rates - jammulinksnews.com
Is NanoViricides Inc. a good long term investmentFree Market Volatility Navigation Tips - jammulinksnews.com
Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency - Global Biodefense
WHO Extended Global Emergency Status of MPox EpidemicDevelopment of Treatment for MPox with NV-387 is Timely, Says NanoViricides - Great Falls Tribune
NanoViricides Advances MPox Treatment Development Amid WHO's Extended Health Emergency - citybuzz -
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency - Proactive financial news
D.C. United Roofing Inc. Wins 2025 Consumer Choice Award for Roofing in Barrie - The Palm Beach Post
NanoViricides Targets Multi-Billion MPox Market with Superior Treatment as WHO Extends Global Emergency - Stock Titan
Go Industries Inc. Unveils Durable Winch Grille Guard for Unmatched Vehicle Protection - The Palm Beach Post
How NanoViricides Inc. stock performs during market volatilityFree Best Stocks to Buy Today - Newser
What makes NanoViricides Inc. stock price move sharplyReal Time Breakout Tracking - Newser
Why NanoViricides Inc. stock attracts strong analyst attention3x Return Stock Radar - Newser
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news
Small cap wrap: Lisata Therapeutics, Uranium American Resources, Nano One Materials... - Proactive financial news
Market movers: Autodesk, Waters, NanoViricides... - Proactive financial news
NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Zacks Small Cap Research
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides - Worcester Telegram
NanoViricides nears completion of clinical trial design for MPox treatment - Proactive financial news
Dallas Central's Welborn Garage Receives 2025 Consumer Choice Award for Garage & Overhead Doors - The Palm Beach Post
Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan
Folsom Homeowners Rejoice: All Pro Overhead Garage Doors Elevates Garage Door Opener Repair Services - Sarasota Herald-Tribune
Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Helios Secures $4M Seed Round to Build First AI-Native Operating System for Public Policy Professionals - The Palm Beach Post
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Milwaukee Journal Sentinel
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Asbury Park Press
PrivateJet.com Launches a New Era in On-Demand Luxury Air Travel - The Arizona Republic
MicroGenDX Transforms Infectious Disease Diagnostics With Innovative 24-Hour Testing Technology - The Daily Jeffersonian
Will Scott Presented “5 Key Insights for Mastering Generative Engine Optimization” at SMX Advanced Boston - Daily Commercial
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case - The Globe and Mail
NanoViricides (NYSE:NNVC) Trading Up 0.7% – Still a Buy? - Defense World
NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox - Proactive Investors
Keathley Landscaping Leads Sod Installation Companies in Wylie with Expert Services - The Palm Beach Post
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate - Worcester Telegram
NanoViricides (NYSE:NNVC) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head Review - Defense World
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan - Knoxville News Sentinel
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu - citybuzz -
Small cap wrap: Fineqia, NanoViricides, Standard Uranium... - Proactive financial news
NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive financial news
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):